DBV Technologies | Ownership
Companies that own DBV Technologies
Janus Capital Management LLC
1,324,747
4.42%
77,906
0.54%
04/10/2018
Amundi Asset Management SA (Investment Management)
969,300
3.23%
53,991
0.07%
01/31/2018
OppenheimerFunds, Inc.
754,989
2.52%
0
0.02%
02/28/2018
The Vanguard Group, Inc.
594,982
1.98%
2,906
0%
07/31/2018
Norges Bank Investment Management
527,396
1.76%
-35,763
0%
12/31/2017
VHCP Management LLC
463,149
1.54%
-153,068
5.32%
06/30/2018
Exane Asset Management SA
285,692
0.95%
-78,890
0.3%
02/28/2018
OrbiMed Advisors LLC
261,044
0.87%
2,243
0.12%
09/30/2017
Invesco Advisers, Inc.
240,195
0.8%
105,448
0.01%
03/29/2018
Invesco Asset Management Ltd.
220,086
0.73%
87,521
0.01%
03/29/2018
| Address |
177-181, avenue Pierre Brossolette
Montrouge Ile-de-France 92120
France
|
|
Employees
|
- |
| Website |
http://www.dbv-technologies.com |
| Updated |
07/08/2019 |
| DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. |
